Literature DB >> 22525148

Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry.

Nina Booken1, Sergij Goerdt, Claus-Detlev Klemke.   

Abstract

BACKGROUND: Primary cutaneous CD30(+) anaplastic large cell lymphomas (C-ALCL) have indolent clinical behavior with an estimated 5-year survival rate of 95%. The clinical features and disease courses of C-ALCL identified in the lymphoma registry of Mannheim University hospital are described in the following. PATIENTS AND METHODS: All C-ALCL patients identified in the database were analyzed in regard to clinical picture, histology, immunohistochemistry, molecular biology, staging, therapy, follow-up, and outcome.
RESULTS: 14 C-ALCL patients were identified. The mean age was 69 years and 57% were men. Solitary skin lesions in one anatomical region were seen in 12 patients upon initial diagnosis. Two patients presented with multiple lesions at different anatomical sites. In 2 patients there was specific lymph node involvement. In one C-ALCL patient, follow-up over 17 months revealed extracutaneous infiltration. Half of the patients relapsed and 36% had multiple episodes. The majority of our patients were treated with surgical excision followed by electron beam radiotherapy. The 5-year survival rate was 93% in C-ALCL.
CONCLUSIONS: The clinical presentation of C-ALCL varies. Staging procedures and a close clinical pathological correlation at initial diagnosis are essential. Due to a high rate of relapses and the possibility of developing extranodal manifestations over the course of the disease, close follow-up is recommended.
© The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin.

Entities:  

Mesh:

Year:  2012        PMID: 22525148     DOI: 10.1111/j.1610-0387.2011.07794.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  8 in total

Review 1.  Update on the Treatment of Anaplastic Large Cell Lymphoma.

Authors:  Khoan Vu; Weiyun Ai
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

2.  Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience.

Authors:  Lynn Million; Esther J Yi; Frank Wu; Rie Von Eyben; Belinda A Campbell; Bouthaina Dabaja; Richard W Tsang; Andrea Ng; Lynn D Wilson; Umberto Ricardi; Youlia Kirova; Richard T Hoppe
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-24       Impact factor: 7.038

3.  A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma.

Authors:  Wen-Tian Lyu; Qi-Bin Song; Wang Qiong; Jing Liu; Ren Yong; Feng-Tao Yi; Dong-Liang Han
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

4.  Primary Lymphomas of the Breast: A Review.

Authors:  Emily R James; Roberto N Miranda; Suzanne D Turner
Journal:  JPRAS Open       Date:  2022-02-20

Review 5.  Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment.

Authors:  Xin-Rui Zhang; Pham-Ngoc Chien; Sun-Young Nam; Chan-Yeong Heo
Journal:  Cancers (Basel)       Date:  2022-03-24       Impact factor: 6.639

6.  Treatment of primary cutaneous anaplastic large cell lymphoma with superficial x-rays.

Authors:  Malene E Jepsen; Robert Gniadecki
Journal:  Dermatol Reports       Date:  2015-03-16

7.  Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma.

Authors:  Grace L Smith; Madeleine Duvic; Zeinab Abou Yehia; Pamela Allen; Naveen Garg; Tina Suki; Sarah A Milgrom; Chelsea C Pinnix; Yasuhiro Oki; Joseph D Khoury; Bouthaina S Dabaja
Journal:  Adv Radiat Oncol       Date:  2017-06-15

Review 8.  Anaplastic Lymphoma Kinase in Cutaneous Malignancies.

Authors:  Severine Cao; Vinod E Nambudiri
Journal:  Cancers (Basel)       Date:  2017-09-12       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.